Zoledronic acid and osteonecrosis of the jaw: incidence varies with use
Wynn, R.L.
General Dentistry 59(5): 330-332
2011
ISSN/ISBN: 0363-6771 PMID: 22313815 Document Number: 654856
Document emailed within 1 workday
Related Documents
Dimopoulos, M.A.; Kastritis, E.; Anagnostopoulos, A.; Melakopoulos, I.; Gika, D.; Moulopoulos, L.A.; Bamia, C.; Terpos, E.; Tsionos, K.; Bamias, A. 2006: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid Haematologica 91(7): 968-971Cohen, P.R. 2015: Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid Dermatology Online Journal 21(8)
Chang, J.T. 2007: Yearly zoledronic acid in postmenopausal osteoporosis New England Journal of Medicine 357(7): 713
Karam, R.; Camm, J.; McClung, M. 2007: Yearly zoledronic acid in postmenopausal osteoporosis New England Journal of Medicine 357(7): 712
De Luca, A.; Normanno, N. 2009: Endocrine therapy plus zoledronic acid in premenopausal breast cancer New England Journal of Medicine 360(22): 2368-2369; Author Reply 2369-2370
Kato, K.; Nagahama, K.; Yagibashi, Y.; Yamamoto, M.; Kanamaru, H.; Hirata, H. 2011: A case of prostate cancer with disseminated carcinomatosis of bone marrow which responded to Zoledronic acid Hinyokika Kiyo. Acta Urologica Japonica 57(6): 331-335
Heymann, P.Günther.Baptist.; Henkenius, K.Sabine.Elisabeth.; Ziebart, T.; Braun, A.; Hirthammer, K.; Halling, F.; Neff, A.; Mandic, R. 2018: Modulation of Tumor Cell Metabolism by Laser Photochemotherapy with Cisplatin or Zoledronic Acid In Vitro Anticancer Research 38(3): 1291-1301
Meng, Y.-h.; Peng, Y.; Liu, D.; Chen, Y.; Wang, H.; Liang, X. 2011: Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells Zhonghua Kou Qiang Yi Xue Za Zhi 46(2): 107-111
Yanae, M.; Nakao, M.; Fujiwara, K.; Kawaguchi, A.; Tsubaki, M.; Chiba, Y.; Morita, T.; Yamazoe, Y.; Nishida, S. 2012: A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(7): 1093-1098
Okagawa, Y.; Sato, Y.; Onuma, H.; Osuga, T.; Hayashi, T.; Sato, T.; Miyanishi, K.; Kobune, M.; Takimoto, R.; Kato, J. 2015: A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(7): 867-870
Koike, K.; Fukami, K.; Morishige, S.; Hazama, T.; Taguchi, K.; Ando, R.; Nagano, M.; Yoshimura, J.; Ueda, S.; Hashiguchi, M.; Tamaki, K.; Nishida, H.; Okuda, S. 2009: Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma Nihon Jinzo Gakkai Shi 51(5): 557-562
McDermott, R.S.; Kloth, D.D.; Wang, H.; Hudes, G.R.; Langer, C.J. 2006: Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model Journal of Supportive Oncology 4(10): 524-529
Murakami, N.; Tanabe, K.; Murasugi, K.; Kadoya, S.; Matsumoto, Y.; Yoshii, I.; Fujikawa, Y.; Ohura, F. 2010: A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(5): 939-942
Natori, T.; Yamaguchi, M. 2013: Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(5): 635-637
Shiono, S.; Harada, M.; Abiko, M.; Sato, T.; Takanashi, I. 2014: A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(6): 757-759
Thanakit, V.; Thinley, U.; Witoonchart, K.; Thuvasethakul, P. 2009: Incidence of osteonecrosis from histopathological study following fracture neck of femur Journal of the Medical Association of Thailand 92(6): 842-847
Kraj, M.; Pogłód, R.; Maj, S.ła.; Owczarska, K. 2006: The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates Acta Poloniae Pharmaceutica 63(5): 450-452
Pectasides, D.; Nikolaou, M.; Farmakis, D.; Kanakis, I.; Gaglia, A.; Kountourakis, P.; Karamanos, N.K.; Economopoulos, T.; Raptis, S.A. 2005: Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid Anticancer Research 25(2b): 1457-1463
Reddy, S.V.; Gupta, S.K. 2012: Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore Medical Journal 53(3): E52-E54
Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.; Coleman, R.E.; Reitsma, D.J.; Seaman, J.J.; Chen, B.L.; Ambros, Y. 2001: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer Journal 7(5): 377-387